Chang Jiang Shang Bao·2025-05-21 23:36Core Viewpoint - 九州通 is actively expanding its strategic investments in the pharmaceutical and healthcare sectors, particularly focusing on medical aesthetics and medical devices through various initiatives and partnerships [1][2][3]. Investment Initiatives - 九州通's wholly-owned subsidiary, 九州通孵化器, has partnered with 北京楚昌私募基金 to establish a new investment fund with a total contribution of 25 million yuan, targeting investments in pharmaceuticals, medical devices, medical aesthetics, and anti-aging sectors [2][3]. - The fund's contributions include 22.99 million yuan from 九州通孵化器, accounting for 91.96% of the total, while the remaining contributions come from other partners [2]. Medical Device Expansion - 九州通 has established a new medical device supply chain company in 湖北孝感 with a registered capital of 10 million yuan, further diversifying its business operations [3]. - In the past three months, 九州通 has launched at least six new medical device companies, indicating a strong commitment to expanding its presence in the medical device sector [3]. - The medical device segment accounted for 22.32% of 九州通's total business last year, with sales revenue reaching 33.887 billion yuan in 2024, reflecting a year-on-year growth of 3.26% [3]. Medical Aesthetics Investment - 九州通 plans to invest 673 million yuan in the restructuring of 奥园美谷, acquiring 360 million shares post-restructuring, which positions the company to become a major stakeholder in the medical aesthetics market [4][6]. - 奥园美谷 has faced financial difficulties but possesses a recognized brand and customer base in the medical aesthetics sector, which 九州通 aims to leverage for growth [4]. - 九州通's medical aesthetics business achieved sales revenue of 851 million yuan in 2024, marking a significant year-on-year increase of 120.47% [4][6]. Historical Context - 九州通 has a history of investing in the medical aesthetics sector, including an early investment in 爱美客 and partnerships with other key players in the industry [5][6]. - The establishment of a dedicated medical aesthetics division and collaboration with upstream manufacturers for product development further underscores 九州通's commitment to this sector [6].